Preschool Wheezing: Trajectories and Long-Term Treatment

Valentina Fainardi, Angelica Santoro and Carlo Caffarelli*

Clinica Pediatrica, Department of Medicine and Surgery, University of Parma, Parma, Italy

Wheezing is very common in infancy affecting one in three children during the first 3 years of life. Several wheeze phenotypes have been identified and most rely on temporal pattern of symptoms. Assessing the risk of asthma development is difficult. Factors predisposing to onset and persistence of wheezing such as breastfeeding, atopy, indoor allergen exposure, environmental tobacco smoke and viral infections are analyzed. Inhaled corticosteroids are recommended as first choice of controller treatment in all preschool children irrespective of phenotype, but they are particularly beneficial in terms of fewer exacerbations in atopic children. Other therapeutic options include the addition of montelukast or the intermittent use of inhaled corticosteroids. Overuse of inhaled steroids must be avoided. Therefore, adherence to treatment and correct administration of the medications need to be checked at every visit.

Keywords: preschool wheezing, phenotype, asthma, therapy, inhaled corticosteroids, skin prick test, allergy, infection

INTRODUCTION

In preschool children, wheezing is very heterogeneous and evidence on pathophysiology and treatment is scant (1). Preschool wheezing should be considered an umbrella term for distinctive diseases with different observable and measurable features (phenotypes). Each phenotype may be the result of different endotypes, described by a mechanism that links clinical features with a molecular pathway. Different approaches have been used in the search of wheezing phenotypes. The selection of observable variables can be driven by the investigator or by data. The design can be cross-sectional or longitudinal. In this review, we discuss knowledge on expression of preschool wheezing phenotypes and their value regarding outcomes, prognosis and long-term treatment.

WHEEZE TRAJECTORIES

About one in three children experiences wheezing during the first 3 years of life (2, 3) but not all will develop asthma in later age (4). Several phenotypes of preschool wheeze that mostly rely on temporal pattern of symptoms have been proposed to identify individuals at risk for asthma onset at school age (1). Other variables including symptoms, bronchial inflammation, allergic sensitization, medication use, and lung function have been also used for classifying subgroups in relation to timing of occurrence and resolution of wheezing.

Birth longitudinal cohort studies have reported numbers of preschool wheeze phenotypes varying from 2 to 6. Three phenotypes are more common (3): (a) transient early wheeze occurs before the age of 3 years and resolves by age of 6 years without lung function impairment; (b) late-onset wheeze develops after 3 years of age and persists in childhood, it is linked to atopy, and, in some studies, it is associated to reduced lung function and high bronchial hyperresponsiveness;
(c) **persistent wheeze** starts in early life before 3 years of age and it is associated with atopy, high IgE levels, early allergen sensitization and diminished lung function by school age (3, 5–13). In Project Viva, a prebirth cohort study in Massachusetts (14), transient-early wheeze and persistent wheeze were found. Children with persistent wheezing or late-onset wheezing more frequently have asthma in adolescence (15).

In the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort, two more phenotypes were identified at 9 years of age (9, 16): (a) **prolonged early wheeze** group (onset between 6 and 54 months of age), not associated with airborne allergen sensitization and weakly associated with higher airway responsiveness and impaired lung function; (b) **intermediate-onset wheeze** group (onset between 18 and 42 months) with persisting symptoms, atopy, poor lung function and at more risk of developing asthma in childhood. At 15 years of age, symptoms continued in school-age-onset persistent phenotype and in late childhood-onset persisting phenotype and in continuous wheeze group and they were associated with bronchodilator reversibility, fractioned exhaled nitric oxide (FeNO) levels ≥35 ppb and impaired pulmonary function (16, 17). Finally, preschool wheeze persisting after 18 months of age is a risk factor for asthma, reduced pulmonary function and higher FeNO value in adolescence (16). Wheezing phenotypes identified in the ALSPAC study have been confirmed by the PIAMA study with the exception of the **prolonged early wheeze** phenotype (13).

In the Manchester Asthma and Allergy Study (MAAS) a new phenotype named **persistent troublesome wheeze**, has been characterized. Children in this category had more frequent exacerbations, hospitalizations, and unscheduled visits, reduced lung function, higher bronchial hyperreactive airways, higher IgE levels to inhalant allergens in comparison with other phenotypes. A sum of medium wheal diameter of skin prick tests (SPT) ≥10 mm and a history of exacerbations by age 3 years predicted persistent troublesome wheeze (8). In the MAAS cohort (18), new phenotypes of children with severe wheeze exacerbations were found when trajectories were examined at 8 years of age and at adolescence. Early-onset frequent exacerbations compared to infrequent exacerbations or no exacerbation had shorter breastfeeding, lower lung function, higher FeNO.

Despite the limitations in categorizing preschool wheeze (1), wheeze trajectories have been used to determine several models for predicting the onset of asthma at school age in high-risk population or in general population (4, 19–31). Unfortunately, the clinical value of predictive indexes for ruling out the development of asthma at school age has been shown to be too low to be adopted in clinical practice (32–34). However, original API is a very promising predictive tool, since it has an appreciable likelihood ratio (~7.4) and it consists only of four clinical parameters and blood eosinophil count (34). Over the last years, many groups attempted to update these definitions and identify more detailed phenotypes using for example latent class analysis (LCA) technique (17, 35, 36) but results from a clinical point of view were rather disappointing.

Several factors that can be potentially modified by simple interventions may change wheeze trajectories. In the Canadian Asthma Primary Prevention Study, pre-school wheezers were classified as **early-transient** (10%) who did not develop asthma, **low-progressive** (69%) who gradually developed asthma over time, and **early-persistent** (21%) with higher risk of asthma occurrence (37). Only in the early-persistent group wheezing prevalence was significantly reduced by intervention including breastfeeding, delayed weaning, avoidance of house dust mite, pets and environmental tobacco smoke.

In the Urban Environment and Childhood Asthma birth cohort, five phenotypes were described (38). Asthma developed in the 60–70% of children with high wheeze/low atopy and high wheeze/high atopy while it was infrequent in low wheeze/high atopy (14%) and in low wheeze/low atopy (1%) and absent in transient wheeze/low atopy. Environmental exposures in early life differed among phenotypes. Maternal stress and depression, prenatal smoke exposure were associated with the high wheeze/low atopy group. Indoor allergen exposure was high in the low wheeze/low atopy group and low in the two high wheeze phenotypes. Household microbial richness and diversity were low in high wheeze/high atopy and highest in transient wheeze/low atopy.

In the French Longitudinal Study of Children, wheezing infants at 2 months of age with 1 or 2 siblings, nocturnal cough, respiratory distress, extreme bronchial secretion, reflux, maternal asthma and maternal smoking during pregnancy were found to be at risk for persistent wheezing at 1 year of age (39).

**VIRUS AND ALLERGY**

In the past, an ERS task force (40) proposed a simple clinical classification of wheezing as “**episodic viral wheezing**” (EVW) or “**multiple trigger wheezing**” (MTW) based on triggers and symptoms. A wheezing typically exacerbated by a viral upper respiratory tract infection with few or no symptoms in the interval between the episodes was described as EVW, the commonest phenotype between 1 and 5 years of age. Children who have symptoms that resemble asthma with wheezing also between respiratory infections and during activity, crying or laughing show the phenotype traditionally called MTW. Children with MTW are usually atopic and may have a family history for asthma. The usefulness of such classification of wheezing in clinical practice is hampered by several factors. It does not consider that is based on patient characteristics at the time of examination (symptom pattern, trigger factors, allergic features...) that change over time (41). Another limitation is that does not take into account the severity of the episodes and cannot identify children responding to specific treatments (42). Furthermore, the two phenotypes can have similarities and cover different endotypes.

In young children, the endotype is difficult to assess because airway samples like bronchoalveolar lavage and bronchial
biopsies are not easy to obtain (43). A research performed on a small sample of preschool children with severe wheeze suggested that EVW might be associated to airway neutrophilia and to airway microbiota dominated by Moraxella although the statistical significance was not reached (44). To date, in young children no study has linked lower airway inflammation or infection to a particular wheeze phenotype (1).

Regarding the Th2 high endotype, Fitzpatrick AM et al. (43) distinguished by LCA four latent classes of recurrent preschool wheeze on the basis of type-2 inflammatory features including blood eosinophils, atopic eczema, aeroallergen and food sensitization and/or pet exposures. The probability of exacerbation was greater in children with sensitization and indoor pet exposure (latent class 2) and children with multiple sensitization and eczema (latent class 4). Overall in children sensitized to aeroallergens this risk was higher than in children with minimal sensitization (latent class 1- sporadic eczema, low blood eosinophils, low serum IgE levels, >90% with no sensitization to aeroallergen and food) or with sensitization plus tobacco smoke exposure (latent class 3) with no exposure to pets. It is not surprising that children with atopic eczema are at risk for exacerbation because airway inflammation has been found in children with atopic eczema without asthma symptoms (45).

Sensitization to foods is more frequent than airborne allergy under 5 years of age (46). It has been shown that asthma that remains over time and severe asthma attacks are more common in children with food allergy and depends on number of offending foods (47). These findings suggest that it may be worthwhile to perform skin prick tests to foods in patients with wheezing and/or atopic eczema (48).

Since atopy is a risk factor for asthma, it has been proposed that probiotics may potentially stimulate Th1 and decrease allergic asthma. Accordingly, there are some data that probiotics supplementation may be of benefit in the prevention of wheeze or asthma (49). Another potential approach is to investigate strategies that prevent viral respiratory tract infections to reduce the development of asthma. However, the impact of probiotics or immunostimulant agents on recurrence of such infections seems to be small (50, 51).

**LONG-TERM THERAPEUTIC APPROACH AND PHENOTYPES**

To date, the optimal therapy for preventing recurrent episodes of wheezing in preschool children is not well-defined and remains a matter of study and debate (52–54). In preschool children, inhaled corticosteroids (ICS) are recommended as first choice of controller treatment in all subjects with frequent exacerbations irrespective of phenotype or endotype (55, 56).

A systematic review of 29 randomized controlled trials (RCTs) in preschool children (no 3,592) showed that ICS reduced the frequency of wheeze episodes independently from phenotype and atopy (57). Similarly, a more recent meta-analysis including 15 studies for a total number of 3,278 children aged ≤6 years demonstrated that daily medium dose ICS reduced the risk of exacerbations by 30% compared to placebo. Moreover, when the analysis was performed in the subgroup of children with persistent asthma the risk of exacerbation was reduced by 44% (53).

The question arises on which preschool children with wheeze may benefit from ICS. The finding of peripheral blood eosinophilia, that in this age group reflects higher airway eosinophilia (58), can suggest the possible response to a continuous therapy with ICS (57). Accordingly, the Individualized Therapy for Asthma in Toddlers (INFANT) trial showed that daily therapy with ICS is beneficial in terms of fewer exacerbations and better symptom control in children aged 12–59 months with aeroallergen sensitization and high blood eosinophils (≥300/µL) (54). Along this line, daily ICS were found to significantly reduce future exacerbations in children with sensitization and indoor pet exposure (latent class 2) and children with multiple sensitization and eczema (latent class 4), but not in children with minimal sensitization (latent class 1) or children with sensitization and second hand tobacco smoke exposure (latent class 3) (43). Therefore, children with MTW experiencing symptoms most days of the week and children with frequent episodes of wheezing (every 6–8 weeks) and/or severe exacerbations requiring systemic corticosteroids irrespective of wheezing phenotype are good candidates to start a trial (at least 6–8 weeks) with daily very low or low dose ICS (Table 1) (55, 57, 59, 60). Other guidelines suggest beginning with moderate dose ICS (56). After a therapeutic trial with ICS for 8–12 weeks, the child should be reassessed to see if symptoms have resolved and treatment can be tapered down or interrupted. Subsequently, ICS treatment should be given again when needed to control symptoms.

In children with mild symptoms aged 6–11 years, the updated GINA recommendations (59) showed a change in the management of wheezing recommending the use of ICS with short acting beta-agonists (SABA) as needed or regular ICS with as needed SABA. However, trials on this issue are lacking in preschool children. The INFANT study showed that some children benefited from as-needed ICS/albuterol as daily ICS or daily montelukast plus as-needed albuterol. Further studies are warranted to clarify endotypes that are associated with response to treatment. If the initial treatment with low dose ICS is not enough to reach good control, various alternatives are available.

**TABLE 1 | Inhaled corticosteroid by recommended dose.**

| Inhaled corticosteroid | Very low dose | Low dose | Medium dose |
|------------------------|--------------|----------|-------------|
| Fluticasone propionate HFA | 50 mcg one puff twice a day | 50 mcg two puffs twice a day | 125 mcg two puffs twice a day |
| Budesonide nebulized | 250 mcg/day | 500 mcg/day | >500–1,000 mcg/day |

Fluticasone and budesonide are considered as pressurized metered dose inhalers (pMDI) with spacer. Adapted from BTS guidelines and GINA recommendations (55, 59). HFA, Hydrofluoroalkane propellant.
(59). The preferred option is doubling the dose (see “medium
dose” in Table 1). The beneficial effects of daily ICS have
been shown up to 400 mcg/day of beclomethasone equivalent
(or 200 mcg/day fluticasone) via pressurized metered-dose
inhaler with spacer without any further improvement for higher
doses (61).

Before increasing or changing the therapy, checking that
the medication is regularly administered and that inhalers
are correctly used is mandatory. Adherence to ICS is crucial
in achieving and maintaining control of symptoms in young
children with wheeze. In an observational study in asthmatic
children aged 2–6 years adherence to ICS was measured
daily for 12 months showing that adherence was the only
determinant significantly associated with asthma control (62).
Moreover, if the child is not too sick to use inhalers, an
MDI/spacer combination is the gold standard strategy to deliver
corticosteroids and bronchodilators and inhalation technique
should regularly checked (63). In those children where regular
intake of low dose ICS plus as-needed SABA fails to control
symptoms or exacerbations, the preferred option is increasing
the dose of ICS (56, 59), after having excluded other diagnosis,
allergen exposure and check adherence to treatment. Latest
recommendations suggest that in children with EIVD and
no signs of atopy adding a leukotriene receptor antagonist
(LTRA), rather than doubling the dose of ICS may be an
option (59, 60). However, RCTs comparing the association of
LTRA plus ICS vs. ICS alone need to be performed before
physicians can recommend this combination in preschoolers.
Moreover, montelukast may cause several adverse effects and
the US Food and Drug Administration has required to add a
boxed warning about mental health side effects. So, the-risk-
benefit balance of montelukast may not be favorable in some
patients, particularly when the symptoms may be mild and
controlled with other drugs (64). When medium dose ICS
does not control symptoms other add-on therapies [LTRA,
long acting beta-agonists (LABA)] in children >4 years of
age) may be considered. Further options include the addition
of theophylline or oral corticosteroids (OCS). Allergen-specific
immunotherapy can be a therapeutic opportunity (65, 66).
It is recommended that all children, including asthmatics,
timely perform vaccinations for infectious diseases and this is
feasible even if they have had allergic reactions to vaccines
(67). It is important that children suffering from asthma
receive influenza and pneumococcal vaccinations. The risk for
invasive pneumococcal disease is declined in asthmatics after
the introduction of pneumococcal vaccination. However, Castro-
Rodriguez JA et al. (68) documented that even among children
who received pneumococcal conjugate vaccine, asthmatic
children were at higher risk for invasive pneumococcal disease
and pneumonia in comparison with non-asthmatic children (68).
Therefore, trials are warranted to assess whether asthmatics
>2 years of age should receive a supplemental 23-valent
pneumococcal polysaccharide vaccination after pneumococcal
conjugate vaccine regardless the intake of high-dose OCS as
reported in the current guidelines in US. Recently the US
Food and Drug Administration and the European Medicines
Agency extended the use of tiotropium as add-on maintenance
treatment in children >6 years of age. Vrijlandt et al. (69)
has found that tiotropium add-on therapy reduced exacerbations in preschool asthma symptoms not controlled by
ICS and LABA or montelukast. Unfortunately, in this study an
association of efficacy of tiotropium with Th2 high endotype was
not determined.

OTHER BASELINE TREATMENTS
The use of intermittent high dose of ICS is an alternative option
in preschool wheeze. In preschool children with EIVD and
who are asymptomatic between the episodes the intermittent use of high
doses of steroids (for example beclomethasone dipropionate 400
mcg twice daily, fluticasone propionate 250 mcg twice daily or
budesonide 1 mg twice daily) at the first sign of respiratory tract
infection and continued for up to 7–10 days may be the preferred
choice (53). Interestingly, this approach is not inferior to daily
steroids also in children at risk of developing asthma (70). A
Cochrane review comparing high ICS doses demonstrated a
reduction in requirement for OCS compared to placebo (71).
Ducharme et al. (52) in a meta-analysis of 4 RCTs (no. 1,024)
reported that compared to placebo, high doses of ICS reduced
the risk of exacerbations requiring OCS in preschoolers with
moderate or severe episodic viral wheeze. A further Cochrane
meta-analysis comparing intermittent ICS with placebo in 490
preschool children with persistent asthma found a reduction
in the need of rescue OCS of almost 50% (72). A more recent
meta-analysis of RCTs showed that, compared to placebo, the
use of intermittent ICS for at least 7–10 days in children with
episodic viral wheeze reduced the risk of exacerbation by 36%.
Interestingly, no significant differences in severe exacerbation
rate were found when this strategy was compared to daily
ICS (53). However, the comparison between intermittent
and continuous therapy yielded controversial results. In the
study by Papi et al. (73) intermittent therapy with nebulized
beclomethasone 800 mcg/day was not inferior to daily low dose
ICS in symptom control but exacerbation rate was lower with
continuous therapy. In contrast, the study by Zeiger et al. (70)
showed no difference between the two treatments in exacerbation
frequency but a significant lower exposure to steroids with
intermittent modality. A 2013 Cochrane meta-analysis including
two trials in preschool children with persistent asthma found
inconclusive evidence about the efficacy of intermittent
vs. daily ICS (74). Though, the meta-analysis by Castro-
Rodriguez evaluating daily and intermittent ICS in preschoolers,
school-aged children and adults with persistent wheezing and
mild to moderate persistent asthma showed no statistically
significant difference in the rate of asthma exacerbations
but more free asthma days in those on daily preventing
therapy (75).

When the use of inhaled steroids is intermittent the prescribed
dose should be enough high to be successful because low-
moderate doses seem to be ineffective (76, 77). Indeed, in
an Italian RCT the intermittent use of 400 mcg of nebulized
beclomethasone twice a day for 10 days did not affect neither
the evolution nor the symptoms of the exacerbation in preschool

Frontiers in Pediatrics | www.frontiersin.org 4 May 2020 | Volume 8 | Article 240
children with viral wheeze (78). However, high doses of steroids imply the use of the highest licensed dose and this is particularly important to avoid an overload of these medications since in this age range children can experience a significant high number of viral exacerbations along the year (76).

Another option for the baseline treatment can be the regular therapy with montelukast, a leukotriene antagonist that modestly reduces symptoms and need for rescue bronchodilator or OCS compared with placebo (79). However, the strength of evidence to support the use of montelukast is limited by the difficulty of the studies in distinguishing EVW from an asthma-like phenotype like MTW. A systematic review and meta-analysis including two RCTs on the use of intermittent or continuous montelukast in children with episodic viral wheeze and no interval symptoms showed that there is no statistically significant difference between the treatment with montelukast and placebo in the number of exacerbations requiring OCS (80). Krawiec et al. (81) reported a similar result in 70 children aged 36 months to 6 years where daily therapy with montelukast did not have any influence in preventing wheeze episodes over 1 year. Furthermore, in comparative studies montelukast is less efficacious than daily steroids in reducing wheeze exacerbations requiring OCS (82). The use of intermittent montelukast in preschool children with wheeze is likely effective only in a specific genotype-dependent subgroup carrying the promoter 5/5 ALOX5 (83).

LIMITATION OF ICS

The effectiveness of ICS for preventing attacks of wheezing in preschool children is always questioned. Very recently, a UK cohort study of children aged 1–5 years reported that initiation of the controller therapy with ICS did not result in fewer exacerbations compared to bronchodilators over 1 year. That said, the electronic data of this study might have represented a very general population of children with mild forms of wheezing since children on ICS before the age of 1 and those prescribed ICS or montelukast during the baseline year were excluded (84). On the other hand, a cohort study including children under 5 years recorded in the same country an increase in ICS prescriptions and treatment of exacerbations over the last 10 years (85). In interpreting these findings it should be considered that prescription of ICS is frequent in children with low tract respiratory infections who do not wheeze. Therefore, choosing the appropriate pharmacological treatment in children with airways disorders is still challenging, a correct diagnostic work up is crucial to avoid inadequate prescriptions (86, 87).

The treatment with continuous or intermittent ICS and the treatment with montelukast do not prevent the progression of any phenotype of preschool wheeze to asthma in later ages but aim to improve symptom control and reduce exacerbations (88–90). The main side effect of a long-term therapy with steroids is growth suppression (91), a topic that should be always discussed with parents. The effects of ICS on growth velocity are seen in pre-pubertal children in the first 1–2 years of treatment resulting in a decrease of 0.5–1 cm in height growth (88). This is not progressive or cumulative and one study on long-term outcomes of continuous ICS showed a difference of 0.7% in adult height (92). It is likely that intermittent treatment has less effect on linear growth because of the lower cumulative dose (53, 70, 74). However, asthma itself as the other chronic diseases, has transient negative impact on growth in children, but the final height is not affected. So, there is a need of trials that investigate whether adult height is reduced by ICS in asthmatics (93). The long-term use of ICS at high doses may have effects on hypothalamic-pituitary-adrenal axis, resulting in reduced adrenal cortisol production (94). However, many studies show a wide variability on the partial suppression of adrenal cortisol, depending on the individual susceptibility, the severity of asthma, the type of inhaled corticosteroid and the inhalation device used. In most cases the suppression is asymptomatic and life-threatening condition are extremely rare. Severe hypoglycaemia due to adrenal insufficiency is reported only in two cases of preschool children treated with inhaled fluticasone propionate at a dosage of 780 µg/m2/day (95).

In the first year of life, symptoms are triggered by viral or bacterial infections. Both atopic and non-atopic wheezers have no eosinophilic airway inflammation (96). Treatment options for controlling symptoms include trials with montelukast or beta2-agonists. Beta2-agonists should be stopped after 4–8 weeks and, when effective, they can be given if necessary. Regarding montelukast, a course of 2–3 months, should be regarded as useful for assessing the efficacy.

CONCLUSIONS

Studies on preschool wheezing phenotypes are of little clinical help for identifying children who are more likely to develop asthma at school age. Drawbacks of such studies include heterogeneous results, with only partial consistency, overlapping features and instability of phenotypes over time. Disagreements between the results may be explained by different study populations, variations in approaches for selecting observational features, lack of uniformity in choosing type and number of variables. Regarding long-term treatment, ICS are the first-line therapy in preschool children with asthma or recurrent wheezing. With the limitations related to a classification based on temporal phenotype, daily ICS are the preferred choice in children with MTW and frequent symptoms, especially those with blood eosinophilia and aeroallergen sensitivity, while intermittent high dose ICS can be considered in children with EVW and no symptoms between the episodes. To date, there is no evidence to recommend the use of intermittent or daily montelukast.

AUTHOR CONTRIBUTIONS

VF, AS, and CC co-wrote the manuscript and approved the final version.
REFERENCES

1. Brand PL, Caudri D, Eber E, Gaillard EA, Garcia-Marcos L, Hedlin G, et al. Classification and pharmacological treatment of preschool wheezing: changes since 2003. * Eur Respir J.* (2014) 43:1172–7. doi: 10.1183/09031936.01199913

2. Bisgaard H, Szele F. Prevalence of asthma-like symptoms in young children. * Pediatr Pulmonol.* (2007) 42:723–8. doi: 10.1002/ppul.20644

3. Martinez FD, Wright AL, Tausig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. * N Engl J Med.* (1995) 332:133–8. doi: 10.1056/NEJM199501193320301

4. Pescatore AM, Dogaru CM, Duembgen L, Silverman M, Gaillard EA, Spycher BD, et al. A simple asthma prediction tool for preschool children with wheeze or cough. * J Allergy Clin Immunol.* (2014) 133:118–8. doi: 10.1016/j.jaci.2013.06.002

5. Howard R, Rattray M, Prosperi M, Custovic A. Distinguishing asthma phenotypes using machine learning approaches. * Curr Allergy Asthma Rep.* (2015) 15:38. doi: 10.1007/s11882-015-0542-0

6. Belgrave DC, Custovic A, Simpson A. Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management. * Expert Rev Clin Immunol.* (2013) 9:921–36. doi: 10.1586/1744666X.2013.836450

7. Delu M, Sperrin M, Belgrave D, Custovic A. Identification of asthma subtypes using clustering methodologies. * PloS ONE.* (2012) 7:48359. doi: 10.1371/journal.pone.0048359

8. Collins SA, Pike KC, Inskip HM, Godfrey KM, Roberts G, Holloway JW, et al. Validation of novel wheeze phenotypes using longitudinal airway function and atopic sensitization data in the first 6 years of life: evidence from the Southampton Women’s survey. * Pediatr Pulmonol.* (2013) 48:683–92. doi: 10.1002/ppul.22766

9. Rusconi F, Galassi C, Corbo GM, Forastiere F, Biggeri A, Ciccone G, et al. Risk factors for early, persistent, and late-onset wheezing in young children. * Am J Respir Crit Care Med.* (1999) 160:1617–22. doi: 10.1164/ajrccm.160.5.9811002

10. Saveneje OE, Granell R, Caudri D, Koppelman GH, Smit HA, Wijsa A, et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALS PAC and PIAMA. * J Allergy Clin Immunol.* (2011) 127:1505–12.e14. doi: 10.1016/j.jaci.2011.02.002

11. Sordillo JE, Coull BA, Rifas-Shiman SL, Wu AC, Lutz SM, Hivert MF, et al. Characterization of longitudinal wheeze phenotypes from infancy to adolescence in Project Viva, a prebirth cohort study. * J Allergy Clin Immunol.* (2020) 145:716–9. doi: 10.1016/j.jaci.2019.10.026

12. Tausig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson children’s respiratory study: 1980 to present. * J Allergy Clin Immunol.* (2003) 111:661–7. doi: 10.1067/mai.2003.162

13. Duijts L, Granell R, Sterne JA, Henderson AJ. Childhood wheezing phenotypes influence asthma, lung function and exhaled nitric oxide fraction in adolescence. * Eur Respir J.* (2016) 47:510–9. doi: 10.1183/13993003.00718-2015

14. Granell R, Henderson J, Sterne JA. Associations of wheezing phenotypes with late asthma outcomes in the avon longitudinal study of parents and children: a population-based birth cohort. * J Allergy Clin Immunol.* (2016) 138:1060–70. doi: 10.1016/j.jaci.2016.01.046

15. Delu M, Fontanella S, Haider S, Sperrin M, Geifman N, Murray C, et al. Longitudinal trajectories of severe wheeze exacerbations from infancy to school age and their association with early-life risk factors and late asthma outcomes. * Clin Exp Allergy.* (2020) 50:315–24. doi: 10.1111/cea.13553
a systematic review with meta-analysis. *Respir Med.* (2013) 107:1133–40. doi: 10.1016/j.rmed.2013.05.005

76. de Benedictis FM, Bush A. Infantile wheeze: rethinking dogma. *Arch Dis Child.* (2017) 102:371–3. doi: 10.1136/archdischild-2016-311639

77. Castro-Rodriguez JA, Custovic A, Ducharme FM. Treatment of asthma in young children: evidence-based recommendations. *Asthma Res Pract.* (2016) 2:5. doi: 10.1186/s40733-016-0020-z

78. Clavenna A, Sequi M, Cartabia M, Fortinguerra F, Borghi M, Bonati M, et al. Effectiveness of nebulized beclomethasone in preventing viral wheezing: an RCT. *Pediatrics.* (2014) 133:505–12. doi: 10.1542/peds.2013-2404

79. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics.* (2001) 108:E48. doi: 10.1542/peds.108.3.e48

80. Brodlie M, Gupta A, Rodriguez-Martinez CE, Castro-Rodriguez JA, Ducharme FM, McKean MC, et al. Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children. *Cochrane Database Syst Rev.* (2015) 10:CD008202. doi: 10.1002/14651858.CD008202.pub2

81. Krawiec M, Strzelak A, Krenke K, Modelska-Wozniak I, Jaworska J, Kulus M, et al. Fluticasone or Montelukast in preschool wheeze. *Clin Pediatr.* (2015) 54:273–81. doi: 10.1177/000992281450158

82. Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. *J Allergy Clin Immunol.* (2007) 120:1043–50. doi: 10.1016/j.jaci.2007.08.063

83. Nwokoro C, Pandya H, Turner S, Eldridge S, Griffiths CJ, Vulliamy T, et al. Montelukast, a leukotriene receptor antagonist in the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics.* (2001) 108:E48. doi: 10.1542/peds.108.3.e48

84. Grigg J, Nibber A, Paton JY, Chisholm A, Guilbert TW, Kaplan M, et al. Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks. *J Asthma Allergy.* (2019) 11:309–17. doi: 10.2147/JAA.S178531

85. Bloom CI, Saglani S, Feary J, Jarvis D, Quint JK. Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016. *Eur Respir J.* (2019) 53:1802130. doi: 10.1183/13993003.02130-2018

86. Mikalsen IB, Dalen I, Karlstand O, Eide GE, Magnus M, Nystad W, et al. Airway symptoms and atopy in young children prescribed asthma medications: a large-scale cohort study. *Pediatr Pulmonol.* (2019) 54:1557–66. doi: 10.1002/ppul.24437

87. Nardini G, Borrelli M, Santamaria F. Asthma treatment of pediatric airway disorders: Choose wisely! *Pediatr Pulmonol.* (2020) 55:11–3. doi: 10.1002/ppul.24550

88. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med.* (2006) 354:1985–97. doi: 10.1056/NEJMoa051378

89. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of inhaled fluticasone dipropionate in wheezy infants (IFWIN): double-blind, randomised controlled study. *Lancet.* (2006) 368:754–62. doi: 10.1016/S0140-6736(06)69285-4

90. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med.* (2006) 354:1998–2005. doi: 10.1056/NEJMoa054692

91. Fuhlbrigge AL, Kelly HW. Inhaled corticosteroids in children: effects on bone mineral density and growth. *Lancet Respir Med.* (2014) 2:487–96. doi: 10.1016/S2213-2600(14)70024-4

92. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. *N Engl J Med.* (2012) 367:904–12. doi: 10.1056/NEJMoa1203229

93. Zhang L, Belizario Lasmar L, Castro-Rodriguez JA. The impact of asthma and its treatment on growth: an evidence-based review. *J Pediatr.* (2019) 1:10–22. doi: 10.1016/j.jpeds.2018.10.005

94. Salvatoni A, Piantanida E, Nozetti I, Nespoli L. Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. *Drug Topics.* (2003) 5:351–61. doi: 10.2165/00128072-200305060-00001

95. Patel I, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. *Arch Dis Child.* (2001) 85:330–4. doi: 10.1136/adc.85.4.330

96. Saglani S, Malmström K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M. Fluticasone or Montelukast in preschool wheeze. *Clin Pediatr.* (2015) 54:273–81. doi: 10.1177/000992281450158

97. Fuhlbrigge AL, Kelly HW. Inhaled corticosteroids in children: evidence-on bone mineral density and growth. *Lancet Respir Med.* (2014) 2:487–96. doi: 10.1016/S2213-2600(14)70024-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2020 Fainardi, Santoro and Caffarelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.